Swedish Orphan Biovitrum AB (publ)
SOBI.ST · Health Technology · Biotechnology · SE
1,377 employees · sobi.com
About
Swedish Orphan Biovitrum AB (Sobi) is a Swedish biotechnology company specializing in rare diseases. It was founded in 1986 as Swedish Orphan International and renamed Swedish Orphan Biovitrum AB (Sobi) in 2007. Sobi is headquartered in Stockholm and is listed on NASDAQ OMX Stockholm. Its business model focuses on developing and marketing therapies for rare diseases with limited treatment options. Sobi operates in Europe, the Middle East, North Africa, and North America, collaborating closely with patient organizations and medical professionals to raise awareness of rare diseases and provide patients with access to important therapies. The company is divided into three business areas: Hemophilia, Inflammatory Diseases, and Genetic Diseases. Sobi offers medications for bleeding disorders, inflammatory diseases, and lysosomal storage diseases, among others. Some of its key products include Elocta and Alprolix for Hemophilia A and B, Kineret for autoinflammatory diseases, Synagis for respiratory syncytial virus (RSV) infections in children, Vimizim for mucopolysaccharidosis type IVA, and Orfadin for hereditary tyrosinemia type 1. In conclusion, Sobi is a leading biotechnology company dedicated to developing and marketing therapies for rare diseases, with a wide range of products in its portfolio. It collaborates with patient organizations and strives to improve the quality of life for patients with rare diseases.
Annual results
Reported figures, SEK · revenue up 8.5% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 28.2B | 478M | 1.7% | — |
| 2024 | 26.0B | 3.9B | 14.9% | — |
| 2023 | 22.1B | 2.4B | 10.9% | — |
| 2022 | 18.8B | 2.6B | 14.0% | — |
| 2021 | 15.5B | 2.7B | 17.3% | — |
SOBI.ST in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Swedish Orphan Biovitrum AB (publ) are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.